Tisch MS News

Ocrelizumab- FDA Approved Treatment of MS

Ocrelizumab (OCREVUS™), an anti-B cell therapy has been approved by the FDA as of March 28th 2017, for the treatment of Relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). This treatment is highly effective for RRMS, based on the data from the Phase III...

May 8, 2017

More

Construction Has Officially Begun on Tisch MS Stem Cell Facility

Construction crews have arrived on site. The build-out has begun!

January 31, 2017

More

Construction to Begin at Tisch MSRCNY on Largest Stem Cell Research Facility Dedicated to MS

Tisch MSRCNY is preparing for construction to commence January 2017 of a state-of-the-art stem cell facility on our 3rd floor. This could not have been done without the generosity of our supporters. The build-out of our new research laboratory enables Phase II of the Tisch MSRCNY FDA-approved stem...

December 8, 2016

More

Support a Future Without MS While Holiday Shopping!

Did you know you’re leaving valuable donations toward a Future Without MS on the table every time you shop on Amazon without connecting to Amazon Smile? What is AmazonSmile? AmazonSmile is a simple and automatic way for you to support the Tisch MS Research Center at no cost to you. When you log on...

December 5, 2016

More

Tisch MSRCNY Holiday Closing

The Tisch MS Research Center of New York will close at 2:00pm on Wednesday, November 23rd and remain closed through the weekend for Thanksgiving. We wish our friends, supporters and patients a very happy and healthy holiday weekend. The Center will re-open on Monday, November 28th, 2016.

November 22, 2016

More

AMY SCHUMER AND PAUL SHAFFER JOIN FORCES TO RAISE $2.5 MILLION FOR MS RESEARCH

Stars Come Out to Help End Multiple Sclerosis at Tisch MS Research Center of New York’s Future Without MS Gala New York, NY- November 1, 2016- The Tisch MS Research Center of New York (Tisch MSRCNY) announced today that their continued efforts to raise $10 million for the Center’s unprecedented...

November 1, 2016

More

Latest Publication from the Tisch MS Research Center: Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.

The following article describes the first clinical use of of intrathecal MSC-NPs in 6 patients with progressive MS. An average followup of 7 years demonstrated both short and long term safety of the treatment. Four of the six patients showed a measurable clinical improvement following MSC-NP...

October 17, 2016

More

Mark Zuckerberg and Priscilla Chan Pledge $3 Billion to Fighting Disease

Like many of you, weare also very excited by the Chan Zuckerberg Initiative announcement. Here’s what we know so far: Rather than funding direct cures, the initiative will fund basic science research, asking questions like how cells divide or how proteins fold. The expectation is that answers to...

September 26, 2016

More

Pages

News Archive

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Look for the IFF Building on the North side of 57th Street across from the CBS building

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.